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Dear Editor,
Coronavirus Disease 2019 (COVID-19) is a viral infec-
tion caused by severe acute respiratory syndrome coronavi-
rus 2 (SARS-CoV-2) with a mortality rate of 3–7% [1]. The 
high mortality results from fulminant pneumonia leading 
to acute respiratory distress syndrome and multiple organ 
failure [2, 3]. Initial reports suggest that comorbidities 
cause a more severe course of infection and a poorer prog-
nosis [4, 5]. Considering the fast spread and high mortal-
ity of COVID-19, it is necessary to understand the possible 
risk factors affecting its progression. We aimed to perform 
a systematic search to evaluate the potential role of all 
reported comorbidities on the disease course. Details of our 
report are provided in Supplementary file 1.
We searched MEDLINE, Embase, Cochrane Central 
Register of Controlled Trials, Web of Science, and Sco-
pus between 01/01/2020 and 05/11/2020. The main 
outcomes were mortality, intensive care unit (ICU) 
admission and severity. Definitions of the investigated 
outcomes are available in Supplementary file 2, Table 2. 
Odds ratios (OR) with 95% confidence intervals (CI) were 
calculated to objectify the association between comorbid-
ities and the outcomes by the random-effects model. The 
study was registered on PROSPERO (CRD42020176781).
Of 33,987 records screened, 61 cohort studies with 
31,089 (median 162; IQR: 103–338) patients were 
included in the meta-analysis. The overall mortality rate 
was 10.0%, 19.9% of patients needed intensive, while 
the reported severity was 24.0%. Underlying chronic 
kidney disease (OR:5.3 CI 3.2–8.7), cardiovascular 
disease (OR:4.7, CI 2.9–7.6), cerebrovascular disease 
(OR:3.9, CI 1.8–8.3), chronic obstructive pulmonary dis-
ease (OR:3.7, CI 2.7–5.1), hypertension (OR:2.7, CI 1.7–
4.4), malignancy (OR:2.6, CI 1.5–4.3), diabetes (OR:2.5, 
CI 1.7–3.6) and immunodeficiency (OR:1.6, CI 1.0–2.5) 
were associated with increased risk of mortality. The 
analysis could not prove that Hepatitis B infection or 
chronic liver disease were associated with mortality due 
to the low number of participants with comorbidities 
(Fig. 1, Suppl. File 2. Figs. 4–13).
Patients with a history of cerebrovascular disease 
(OR:3.5, CI 1.9–6.5), chronic obstructive pulmonary dis-
ease (OR:2.2, CI 1.5–3.4), cardiovascular disease (OR:2.1, 
CI 1.5–3.0), hypertension (OR:1.9, CI 1.5–2.5), diabetes 
(OR:1.8, CI 1.3–2.5), malignancy (OR:1.7, CI 1.0–2.7) 
needed intensive care more often. The analysis could 
not prove that chronic liver disease, immunodeficiency, 
chronic kidney disease and hepatitis B infection were 
associated with higher admission rate to ICU (Supp. File 
1. Fig. 2.; Suppl. File 2. Figs. 4–13).
Results regarding severity are shown in Supplementary 
file 1, Fig.  3. Reports on comorbidities not eligible for 
meta-analysis are summarized in Supplementary file 2, 
Table 6.
In summary, cerebrovascular disease, chronic obstruc-
tive pulmonary disease, cardiovascular disease, hyper-
tension, diabetes mellitus, malignancy are significant 
risk factors for poor clinical outcome in COVID-19. Our 
findings emphasize the critical role of comorbidities in 
the course of COVID-19. These results could be used for 
risk stratification of patients infected with SARS-CoV-2 
and should be taken into consideration when establish-
ing a prognostic tool. Although no specific treatment has 
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been identified for COVID-19 yet, these results should be 
considered when applying prevention and therapy.
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5.28 (3.19-8.72) 50/95 (53%) 348/1463 (24%) 0% 6% 9
4.72 (2.92-7.64) 248/1526 (16%) 818/9925 (8%) 64.6% 13% 13
3.89 (1.84-8.25) 28/52 (54%) 274/1176 (23%) 31.8% 4% 7
3.67 (2.65-5.08) 108/396 (27%) 983/11239 (9%) 9.9% 3% 14
2.73 (1.71-4.35) 392/2953 (13%) 674/8019 (8%) 83.8% 27% 13
2.58 (1.53-4.34) 34/87 (39%) 498/2411 (21%) 0% 3% 11
2.45 (1.68-3.56) 225/1558 (14%) 841/9414 (9%) 61.2% 14% 13
1.61 (1.04-2.5) 23/253 (9%) 638/9133 (7%) 0% 3% 2
1.2 (0.36-4.02) 5/11 (45%) 108/263 (41%) - 4% 1
1.14 (0.27-4.81) 3/9 (33%) 101/298 (34%) 0% 31% 3
Fig. 1 Summary figure for odds ratios (OR) with 95% confidence interval (95% CI) of mortality for different comorbidities. Forest plots with pooled 
ORs can be found in Suppl.File 2, Figs. 4–13. 95% CI confidence interval, CKD chronic kidney disease, CVD cardiovascular disease, CeVD cerebrovas-
cular disease, COPD chronic obstructive pulmonary disease, HT hypertension, MALI malignancy, DM diabetes mellitus, ID immunodeficiency, HepB 
Hepatitis B, CLD chronic liver disease, I2 heterogeneity, n number of articles included, OR odds ratio
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